"Additionally, the FDA recently notified the Company that the REMS is no longer necessary to ensure the benefits of FILSPARI outweigh the risk of embryo-fetal toxicity and to minimize the burden on the healthcare delivery system. The Company plans to submit a REMS modification to remove the need to monitor the risk of embryo-fetal toxicity as an amendment to the REMS sNDA currently under review for potential modification of liver monitoring."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
-0.005(1.05%) |
Mkt cap ! $282.0M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.3¢ | 46.5¢ | $1.188M | 2.509M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 28330 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 48233 | 4 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |